Danish drugmaker Novo Nordisk said the U.S. Food and drug Administration has delayed providing feedback on its once-a-day Type 2 diabetes drug Victoza, according to a recent article from Reuters.
Analysts had been expecting feedback on the drug, known as liraglutide in Europe, by the end of the year. The drug pushes the body to release extra insulin when blood sugar levels run high. It has been approved in Europe, but regulatory approval has been delayed in the U.S., a cause for concern to some. A Novo spokesman said the company is convinced there is no need for alarm and that the approval process is simply taking longer than normal. The company expects formal feedback within weeks. If it does not get it, it will provide an update on the drug on Feb. 2, 2010, along with its financial results.
Victoza expects to compete with Byetta from Eli Lilly and Amylin Pharmaceuticals. GlaxoSmithKline and Roche Holding AG are also developing drugs in the same class.
To receive free news updates from Diabetes News Hound delivered straight to your Inbox, sign up here.
If you already receive the free Alerts, spread the word by telling a friend to sign up here .
